全文获取类型
收费全文 | 38031篇 |
免费 | 2839篇 |
国内免费 | 1098篇 |
专业分类
耳鼻咽喉 | 84篇 |
儿科学 | 893篇 |
妇产科学 | 552篇 |
基础医学 | 2017篇 |
口腔科学 | 633篇 |
临床医学 | 4720篇 |
内科学 | 12352篇 |
皮肤病学 | 182篇 |
神经病学 | 721篇 |
特种医学 | 566篇 |
外科学 | 2332篇 |
综合类 | 7836篇 |
现状与发展 | 2篇 |
一般理论 | 1篇 |
预防医学 | 2928篇 |
眼科学 | 632篇 |
药学 | 3781篇 |
25篇 | |
中国医学 | 1487篇 |
肿瘤学 | 224篇 |
出版年
2024年 | 80篇 |
2023年 | 598篇 |
2022年 | 962篇 |
2021年 | 1626篇 |
2020年 | 1496篇 |
2019年 | 1150篇 |
2018年 | 1268篇 |
2017年 | 1232篇 |
2016年 | 1361篇 |
2015年 | 1370篇 |
2014年 | 2639篇 |
2013年 | 2730篇 |
2012年 | 2501篇 |
2011年 | 2826篇 |
2010年 | 2151篇 |
2009年 | 2062篇 |
2008年 | 1948篇 |
2007年 | 1940篇 |
2006年 | 1658篇 |
2005年 | 1485篇 |
2004年 | 1218篇 |
2003年 | 967篇 |
2002年 | 750篇 |
2001年 | 740篇 |
2000年 | 624篇 |
1999年 | 551篇 |
1998年 | 470篇 |
1997年 | 460篇 |
1996年 | 376篇 |
1995年 | 339篇 |
1994年 | 294篇 |
1993年 | 303篇 |
1992年 | 279篇 |
1991年 | 206篇 |
1990年 | 183篇 |
1989年 | 179篇 |
1988年 | 149篇 |
1987年 | 115篇 |
1986年 | 110篇 |
1985年 | 112篇 |
1984年 | 83篇 |
1983年 | 37篇 |
1982年 | 67篇 |
1981年 | 39篇 |
1980年 | 45篇 |
1979年 | 27篇 |
1978年 | 37篇 |
1977年 | 23篇 |
1975年 | 14篇 |
1973年 | 16篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
目的 探讨糖尿病合并结核潜伏感染的研究现状、热点与前沿。方法 收集Web of Science核心合集于2000年1月1日至2021年11月20日发表的糖尿病合并结核潜伏感染的相关文章,运用CiteSpace 5.8.R3软件进行可视化分析。结果 共纳入英文文献148篇,近20年来该领域发文量呈上升趋势。美国发文量最多(46篇, 31.08%),机构间合作情况的可视化分析共得到个340节点、929条连线,网络密度为0.0161,作者间合作关系的知识图谱共得到790个节点、2425条连线,网络密度为0.0078,关键词共现分析结果显示,糖尿病合并结核潜伏感染的危险因素、患病率、诊断和治疗是该领域的研究热点和趋势。结论 糖尿病合并结核潜伏感染的发文量不断增加,机构间、区域内和国际范围内的合作有待进一步开展。立足国情,探索慢病共病的管理模式将有助于优化共病管理,进一步推动慢病管理的进程。 相似文献
2.
3.
《Obesity research & clinical practice》2022,16(2):138-143
BackgroundOverweight and obesity have been observed in children with type 1 diabetes (T1D). This further increases their future risk of Cardiovascular Disease (CVD) as well as the development of other risk factors, such as dyslipidemia.AimsTo compare lipid profiles in children and adolescents with Type 1 diabetes and lean mass (T1L), Type 1 diabetes and overweight or obese (T1OW/OB), and type 2 diabetes (T2D).MethodsThis was a cross-sectional study of 669 patients with T1D or T2D aged 2–19 years using retrospective data collected from 2003 to 2014. Included patients were categorized into lean (BMI < 85th ile and overweight or Obese (BMI ≥ 85th ile). Patients were subcategorized into three age groups: < 10 years, 10–14 years, and 15–19 years.Results7.6% of patients had T2D. Of the patients with T1D, 58.9% were lean, 26.4% were overweight, and 14.7% were obese. Total Cholesterol (TC), Low-density lipoprotein cholesterol (LDL-C) and Non-HDL-C levels were similar across groups. In the 15–19 years group, Triglycerides (TG) levels were significantly higher in T1OW/OB and similar to T2D. High-density lipoprotein Cholesterol (HDL-C) was significantly lower in T2D. Weight status significantly correlated with TG and HDL-C levels in T1D and T2D groups.ConclusionsT1OW/OB constitutes a significant proportion of the T1D population. Patients with obesity and T1D, especially if in their late adolescence, have an adverse lipid profile pattern that is comparable to adolescents with T2D. Based on these findings, risk for future CVD in T1OW/OB and T2D may be equivalent. 相似文献
4.
5.
BACKGROUND Metabolic disturbances including changes in serum calcium,magnesium or phosphate(P) influence the prevalence of type 2 diabetes mellitus(DM).We assessed the importance of serum P in elderly patients with type 2 DM vs nondiabetes mellitus(non-DM) in relation to renal function.AIM To determine the association between serum P and serum glucose or insulin resistance in diabetic and non-diabetic patients.METHODS One hundred-ten subjects with a mean age of 69.02±14.3 years were enrolled.Twenty-nine of the participants had type 2 DM(26.4%).The incidence of hypertension,smoking and receiving vitamin D(vitD) derivates were recorded.The participants were classified by both estimated glomerular filtration rate(eGFR) and albuminuria categories according to the Kidney Disease Improving Global Outcomes 2012 criteria.RESULTS We divided the patients in two groups according to the P cut-off point related to DM value.A comparison between high and low P showed that body mass index30.2±6.3 vs 28.1±4.6(P=0.04),mean glucose 63.6 vs 50.2(P=0.03),uric acid 6.7±1.6 vs 6.09±1.7(P=0.05),mean intact-parathyroid hormone 68.06 vs 47.4(P=0.001),systolic blood pressure 147.4±16.7 vs 140..2±16.1(P=0.02),mean albuminuria 63.2 vs 50.6(P=0.04) and eGFR 45.6±22.1 vs 55.4±21.5(P=0.02)were significantly different.χ~2 tests showed a significant association between high P and DM,hypertension,receiving vitD,smoking and eGFR stage(χ~2=6.3,P=0.01,χ~2=3.9,P=0.03,χ~2=6.9,P=0.009,χ~2=7.04,P=0.01 and χ~2=7.36,P=0.04,respectively).The adjusted model showed that older age,female gender and increased body mass index were significant predictors of type 2 DM when entering the covariates.CONCLUSION High serum P contributes to vascular and metabolic disturbances in elderly patients with type 2 DM and renal impairment. 相似文献
6.
7.
Niya Narayanan Dukhabandhu Naik Jayaprakash Sahoo Sadishkumar Kamalanathan 《World Journal of Virology》2022,11(6):399-410
Coronavirus disease 2019 (COVID-19) is associated with a high risk of mortality and complications in patients with diabetes mellitus. Achieving good glycemic control is very important in diabetic patients to reduce complications and mortality due to COVID-19. Recent studies have shown the mortality benefit and anti-inflammatory effects of Dipeptidyl-peptidase-4 inhibitors (DPP-4i) in diabetic patients with COVID-19. DPP-4i may have a beneficial role in halting the severity of infection primarily by three routes, namely viral entry inhibition, anti-inflammatory and anti-fibrotic effects and glycemic control. This has raised the pro-mising hypothesis that DPP-4i might be an optimal strategy for treating COVID-19 in patients with diabetes. This review aims to summarise the possible therapeutic non-glycemic effects of DPP-4i in diabetic patients diagnosed with COVID-19 in the light of available evidence. 相似文献
8.
《Diabetes & Metabolic Syndrome: Clinical Research & Reviews》2019,13(4):2445-2449
Diabetes mellitus is a chronic metabolic disorder that has a complex molecular and cellular pathophysiology, resulting in its dynamic progression and that may show differing responses to therapy. The incidence of diabetes mellitus increases with age and requires additive therapeutic agents for its management. SGLT2i and DPP-4 inhibitors and GLP-1 receptor agonists (GLP-1RA) are newly introduced antidiabetic drugs that work through differing mechanisms; DPP-4 inhibitors maintain the endogenous level of GLP1; GLP-1RA result in pharmacological levels of GLP1, whilst SGLT2i act on the proximal tubules of the kidney. They have shown efficacy in the management of diabetes and in contrast to other antidiabetic drugs, do not inherently cause hypoglycemia in therapeutic doses. Autophagy as a highly conserved mechanism to maintain cell survival and homeostasis by degradation of damaged or aged organelles and components, and recognised to be increasingly important in diabetes. In the present review, we discuss the modulatory effects of these newly introduced antidiabetic drugs on the autophagy process. 相似文献
9.
10.
Alexander Real Chierika Ukogu Divya Krishnamoorthy Nicole Zubizarreta Samuel K. Cho Andrew C. Hecht James C. Iatridis 《The spine journal》2019,19(2):225-231